BioNxt Solutions Inc. (CVE:BNXT) | Finanzwire

Basculer en Français

9475	Companies
185452	Keywords
117799	Articles
99307	Press releases

Headlines Articles Press releases BioNxt Solutions Inc.

Home
Companies
BioNxt Solutions Inc.

BRIEF

published on 08/23/2025 at 02:10, 3 months 13 days ago

BioNxt Solutions Engages in Investor Relations Initiatives

Brand Visibility Investor Relations BioNxt Solutions Apaton Finance Cayo Ventures
PRESS RELEASE

published on 08/23/2025 at 02:05, 3 months 13 days ago

Promotional Activity Engagements
BioNxt Solutions Inc. engages Apaton Finance GmbH and Cayo Ventures GmbH for investor relations services. Apaton to enhance brand visibility, Cayo for digital marketing to drive website traffic

Digital Marketing Investor Relations BioNxt Solutions Inc. Apaton Finance GmbH Cayo Ventures GmbH
BRIEF

published on 08/20/2025 at 09:10, 3 months 16 days ago

BioNxt Solutions Accelerates U.S. Patent and Secures Broad IP for Neurological Autoimmune Disorders

Cladribine BioNxt Solutions U.S. Patent MS Treatment Sublingual Thin-Film
PRESS RELEASE

published on 08/20/2025 at 09:05, 3 months 16 days ago

BioNxt Fast-Tracks U.S. Patent for MS Drug and Secures Broad Platform IP Covering Autoimmune Neurology Pipeline
BioNxt announces fast-tracked U.S. patent filing for BNT23001 sublingual thin-film cladribine formulation targeting neurological autoimmune disorders. Broad international patent core claims accepted for platform-level protection

Autoimmune Diseases Drug Delivery Neurological Disorders Patent Filing BioNxt
BRIEF

published on 08/09/2025 at 01:05, 3 months 27 days ago

BioNxt Solutions Completes Oversubscribed Convertible Debenture Offering

Private Placement Convertible Debenture Warrants Product Development BioNxt Solutions
PRESS RELEASE

published on 08/09/2025 at 01:00, 3 months 27 days ago

BioNxt Solutions Announces Closing of Final Tranche of Oversubscribed Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising $241,200 for convertible debentures and issuing Warrants. Funds intended for product development and IP filings

Private Placement Warrants Convertible Debentures BioNxt Solutions Inc. Product Development
BRIEF

published on 08/05/2025 at 09:10, 4 months ago

BioNxt Solutions Advances Patent Protection for MS Treatment

Multiple Sclerosis Drug Delivery Technology Patent Protection BioNxt Solutions Sublingual Cladribine
PRESS RELEASE

published on 08/05/2025 at 09:05, 4 months ago

BioNxt Solutions Reports Pending Patent Grants in Europe and Eurasia, Strengthening IP Protection for Proprietary Sublingual Cladribine-Based MS Treatment
BioNxt Solutions Inc. makes significant progress in global patent portfolio with EPO and EAPO confirming acceptance of core claims for sublingual Cladribine thin-film formulation. Focus on innovation in MS treatment

BioNxt Solutions Inc. Patent Portfolio Cladribine EPO EAPO
BRIEF

published on 07/26/2025 at 00:05, 4 months 10 days ago

BioNxt Solutions Closes First Tranche of Debenture Placement

Private Placement Warrants Convertible Debentures Product Development BioNxt Solutions
PRESS RELEASE

published on 07/26/2025 at 00:00, 4 months 10 days ago

BioNxt Solutions Announces Closing of First Tranche of Convertible Debenture Unit Private Placement
BioNxt Solutions Inc. closes first tranche of non-brokered private placement, raising $1,009,200 for drug delivery tech and IP development. Securities subject to statutory hold until Nov 26, 2025

Private Placement Convertible Debentures BioNxt Solutions Inc. Intellectual Property Drug Delivery Technologies

Accesswire

Published on 12/05/2025 at 02:35, 10 hours 53 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 10 hours 58 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 12 hours 28 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 23 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 28 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:00, 27 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 27 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 22 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 27 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 27 minutes ago

Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million

Les Echos

Published on 12/05/2025 at 08:45, 4 hours 43 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 19 hours 28 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 19 hours 43 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 19 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 6 hours ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health

View all LES ECHOS COMFI WIRE